The various guidelines for the administration of tetanus toxoid and antitetanus immunoglobulin are not only complicated, but also have never been supported by any scientific experimental studies. This study has measured the antibody levels in a random sample of 157 patients presenting to an accident and emergency department. Levels were measured before and after boosting doses. The results show that, in the sample analyzed, even those patients who had their last 'booster' over 10 years ago, had a satisfactory immunoglobulin level. In fact, no patient in the study had a level below the 'protective level'. Bearing in mind the small number of patients in the study, it could be argued that the level of immunity against tetanus in the United Kingdom is likely to be higher than assumed. If this is proven to be correct, then the length of time between booster injections of toxoid can be extended and the use of Human Antitetanus Immunoglobulin can be further restricted.
INTRODUCTION
The treatment of tetanus, even today, is prolonged, costly and not always rewarded with success (Edmonson & Flowers, 1979) . It is, therefore, imperative to make every effort to prevent this infection. The last decade has witnessed some improvement in the understanding of the prophylaxis of this disease. In the UK, the reported incidence of tetanus has fallen sharply in the last few years. However, it is believed that the actual number of cases is four to five times the number of notifications (PHLS, 1982; PHLS, 1985) .
The importance of the Primary Immunization Course is undisputed. The teaching that the mainstay in the prevention of tetanus is the meticulous surgical cleansing of the wound remains paramount. The second step advocated by all concerned is immunization. It has been postulated that, as the antitoxin level can fall after a period of time, a toxoid 'booster' is necessary. Various guidelines for the use of the toxoid and the immunoglobulin exist (Smith et al., 1975; DHSS, 1984 ; American College of Emergency Physicians, 1986) . Unfortunately, these guidelines are not uniformly adopted. A survey in 1984 showed that, although a good proportion of the accident and emergency (A&E) departments in the UK followed the policy advocated by Smith et al., in 1975, there was a wide variation in the usage of the vaccine and immunoglobulin (Marrow, 1986) . A search of the literature revealed that no recent experimental work has been conducted on a random sample of population to make any suggested regimen a rational one.
In the presence of necrotic and devitalized tissues, the spore-forming anaerobic clostridium tetani produce an exotoxin: a potent neurotoxin with lethal effects. Thus, tetanus can be classified as a localized infection with devastating generalized manifestations. The first method of prophylaxis is surgical ablation of any sanctuary where organisms could survive. The second is to have an adequate concentration of a specific antitoxin circulating in the blood to neutralize the toxin. In many epidemiological studies, the protective level of antitoxin was accepted to be 0-01 Units/ml of serum. This was first estimated by Captain Sneath (Sneath et al., 1937) and was later confirmed by demonstrating that at such a level, a challenge with '2-3 fatal doses' produced no tetanus symptoms in human subjects (Wolters & Dehmel, 1942) . Other authors also concluded that an antitoxin level of 0O01 U/ml was sufficient to confer protection against tetanus (Scheibel, 1955; Tasman & Huygen, 1962) .
Milton Keynes, England, is a new city built with futuristic features. The roads are designed as a grid square system thus facilitating transport and communications. It has a well-demarcated population living in large estates. The population consists predominantly of young people, with a small proportion of senior citizens. Due to the advanced planning, each of these estates has its own general practitioner. Since the opening of the hospital, each GP has been informed-in writing-of the attendances of his patients to the A&E department on a daily basis.
The current practice in the A&E department in Milton Keynes is that, in the presence of a wound, the patient is considered immune if he has had a full primary course and a booster within the last 5 years. If between 5 and 10 years have elapsed since the last toxoid and the wound is less than 6-h old, with little devitalized tissue and cleanable, the patient is considered partially immune and merits a booster dose of toxoid. However, if more than 10 years have elapsed since the last boost, the wound is more than 6-h old, or difficult to debride, or the patient has not received a full primary immunization course, then the patient is offered 250 units of human tetanus immunoglobulin as well as the first dose of a full course. He/she is then advised to complete the course through his/her general practitioner (GP) and the GP is informed in writing. The policy of informing the GP's daily has insured full cooperation regarding filling-in the simple questionnaire used in this study.
PURPOSE OF THE STUDY
The purpose of this study was to quantitatively measure the levels of tetanus antibodies circulating in the blood stream. The relationship between the time elapsed since last exposure to vaccination and the level of circulating antibody would, thus, be defined. Based on these results, it should be possible to demonstrate whether the immunity against tetanus is satisfactory if more than 10 years have elapsed since the last vaccination and if a simple booster dose-rather than a full course-is all that is required to boost the antibody level to more than 0-01 U/ml.
For the purpose of this study, the patients were allocated to one of three categories viz A, B or C depending on the immunization history. Patients who had been exposed to tetanus toxoid boosters in the last five years were grouped under category A. Those patients who were last exposed to tetanus toxoid between 5 and 10 years before were grouped as category B. Finally, those who were exposed to tetanus toxoid more than 10 years before were grouped under category C.
METHOD
Due approval of the local Medical Ethics Committee was obtained. Assurance was given that no patient would be forced to be immunized.
Any person over 16 years old presenting to the A&E department was eligible to enter the study, regardless of the need for tetanus immunization. No upper age limit was imposed. Eligible patients were examined, the history of tetanus immunization, carefully recorded and then treated conventionally. The patient was then informed of the purpose of the study, his/her consent obtained and 5 ml of venous blood were taken. Confidentiality was preserved by identifying the blood samples with only a serial number. Each patient in the study was then given a questionnaire addressed to his/her GP. This enquired about the recorded tetanus immunization history. Replies were entered in a special register.
The blood samples were delivered to the Pharmacological Unit laboratories of Hoechst UK in Milton Keynes. There, the blood was separated and the serum frozen. The relatively new Tetanus IgG Enzyme Immunoassay (EAI) method was used. The test kits are commercially available from Labsystems (UK) Ltd. The resulting colour reaction was read with a single-channel photometer. Results were entered in the appropriate column in the register.
Those patients who were given a booster with or without immunoglobulin were requested to return after 4-6 weeks for a repeat test. An appropriate reminder was sent near the time.
RESULTS
One hundred and fifty-seven patients were entered in this study. There were 50 patients in group A (fully immune), 53 patients in group B (partially immune) and 54 patients in group C (non-immune). The distribution by age, sex and immunity group is shown in Fig. 1 . The age of the patients ranged from 16 to 85 years old and the distribution reflects the relatively young population of Milton Keynes. One hundred and fifty-one replies from GPs were obtained. The remaining six were patients living outside the district. In 97 cases, no record of tetanus immunization existed in the GP's notes. In 36 patients, the history was confirmed to be correct by the GP and for the remaining 24 patients there was discrepancy between the GP's records and the history given by the patient (Table 1) .
The lowest antibody level detected was 0-013 U/ml, whereas nine patients had a level higher than 10 U/ml. Tables 2 and 3 show the analysis of data by immunity groups and by age groups, respectively. Of those patients who received a booster dose with or without immunoglobulin, only 23 returned after 4-6 weeks. Table 4 shows the mean change in the level of antibody before and after the booster dose of toxoid. A more detailed account of these patients showing the individual changes in antibody level is given in Table 5 .
One patient entered in the study was a 21-year-old female who did not receive the primary immunization course during childhood. This was because her elder brother had a severe reaction to the triple vaccine and the parents decided not to immunize the other children. This history was verified and confirmed by the GP. Whatever immunity she had was a naturally acquired one. She had an antibody level of 0-12 U/ml. This patient refused any immunization on her recent visit.
Two diabetic patients aged 58 and 46 in whom the last exposure to tetanus toxoid was more than 10 years ago had antibody levels of 0-21 and 0 59 U/ml, respectively. Another patient successfully treated for Hodgkin lymphoma-having survived 5 years after immunosuppression-and who was last exposed to tetanus toxoid more than 10 years ago, had an antibody level of 0 03 U/ml at her first visit. The post-booster antibody level rose to 0-19 U/ml.
DISCUSSION
The relatively small number of patients with vaccination history confirmed to be correct by their GP reflects the difficulty of maintaining good immunization records. This problem would occur if the GP is not notified about any given boosters by either the patient or the A&E department giving it. There is also an inevitable delay in the transfer of medical records of those who have recently moved in the district. In the absence of suitable verification, it is, therefore, difficult to comment on the general awareness of the patients towards their vaccination history. The vast improvement in the prevention of tetanus is the combined result of active immunization, improved wound care and the use of specific tetanus immunoglobulin.
The comprehensive guidelines given by Smith et al. (1975) stressed the importance of all these factors. These were later updated but remained largely based on empirical grounds. Also, as these guidelines are quite complex, there is a risk of inaccuracy in applying them (Brand et al., 1983; Giangrasso & Smith, 1985) . The few workers in the field who measured the level of tetanus antibody did so in select groups of people with easily traceable histories of immunization (Gottlieb et al., 1964; Worman et al., 1963; Peebles et al., 1969; White et al., 1969; Collier et al., 1979) . In the present study, a random sample of patients was tested, with no age preference and patients with no wounds had no reason to conceal information about their immune state. Therefore, the sample represents a true cross section of the Milton Keynes population.
The most significant finding of this study is that, regardless of age group or immunization history, no patient had a level below the accepted protective level of 0-01 U/ml. Furthermore, almost all patients who returned 4-6 weeks after the booster dose, showed an increase in the antibody level. The range of change varied from minimal to over a hundred-fold increase after a single booster.
Not forgetting the limitation of this present study, the last two findings should give confidence in simplifying the guidelines for tetanus immunization in the A&E department. The 5 years boosters are probably not necessary. A 'wound' booster at around the 10 years interval should be recommended. Also there is no need for a full course of toxoid if the patient was immunized at any time in the past. Human Antitetanus Immunoglobulin should be reserved for use only in cases where no primary childhood immunization was given, or if the wound is treated after 6 h and proper surgical toilet of the wound is not practicable. As more immunoglobulin is imported, there is the added risk-albeit remote-of unwanted contamination with the HIV. By rationalizing the use of the immunoglobulin, the risk should be further reduced. Primary childhood immunization and surgical toilet remain of utmost importance. It is the authors' hope that a further study, perhaps on a different population, and on a larger scale could be conducted. 
